Adding Smoking Cessation Estimated to Increase QALY and Lower Cost of Screening by 20 to 45%
Projected 15-year costs and quality-adjusted life years saved by lung cancer screening and treatment with and without smoking cessation using stage shifts from NY-ELCAP and NLST in authors' actuarial model. | |||
---|---|---|---|
NY-ELCAP stage shift | NLST stage shift | ||
Screening |
|||
Lung cancer |
$27,824,282,242 |
$34,054,299,361 |
|
QALYs saved by screening and treatment |
985,284 |
722,795 |
|
Cost per QALY saved |
$28,240 |
$47,115 |
|
Screening + light smoking cessation intervention |
|||
Additional costs for cessation |
$1,361,556,665 |
$1,361,556,665 |
|
Additional QALYs saved by cessation |
273,566 |
273,566 |
|
Cost per QALY saved |
$23,185 |
$35,545 |
|
Screening + intensive smoking cessation intervention |
|||
A. NRT generic plus behavioral |
|||
Additional costs for cessation |
$3,212,191,737 |
$3,212,191,737 |
|
Additional QALYs saved by cessation |
930,754 |
930,754 |
|
Cost per QALY saved |
$16,198 |
$22,537 |
|
B. Bupropion generic plus behavioral |
|||
Additional costs for cessation |
$4,088,822,965 |
$4,088,822,965 |
|
Additional QALYs saved by cessation |
930,754 |
930,754 |
|
Cost per QALY saved |
$16,656 |
$23,067 |
|
C. Chantix plus behavioral |
|||
Additional costs for cessation |
$5,342,861,783 |
$5,342,861,783 |
|
Additional QALYs saved by cessation |
930,754 |
930,754 |
|
Cost per QALY saved |
$17,310 |
$23,826 |
NY-ELCAP, New York Early Lung Cancer Action Project; NLST, National Lung Screening Trial; QALY, quality-adjusted life year. doi:10.1371/journal.pone.0071379.t002
Villanti, Andrea & Jiang, Yiding & Abrams, David & Pyenson, Bruce. (2013). A Cost-Utility Analysis of Lung Cancer Screening and the Additional Benefits of Incorporating Smoking Cessation Interventions. PloS one. 8. e71379. 10.1371/journal.pone.0071379.